Supplemental Figure 2. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
Supplementary Figure 2.
Real world data on treatment outcomes in EGFR mutant NSCLC patients receiving
osimertinib in second or further lines
Univariate odds ratios for progression pattern. An odds ratio > 1 shows an association with EGFR T790M mutation, whereas an odds ratio < 1 with EGFR T790M mutation negativity. 95% confidence intervals for odds ratios are plotted. PD, progression.